Phase I trial of adoptively transferred tumor-infiltrating lymphocyte immunotherapy following concurrent chemoradiotherapy in patients with locoregionally advanced nasopharyngeal carcinoma

OncoImmunology

Volumn 4, Issue 2, 2015, Pages 1-10

  Li, Jiang ^a   Chen, Qiu Yan ^a,b   He, Jia ^a   Li, Ze Lei ^a   Tang, Xiao Feng ^a   Chen, Shi Ping ^a   Xie, Chuan Miao ^a   Li, Yong Qiang ^a   Huang, Li Xi ^a   Ye, Shu Bio ^a   Ke, Miao La ^a   Tang, Lin Quan ^a,b   Liu, Huai ^a,b   Zhang, Lu ^a,b   Guo, Shan Shan ^a,b   Xia, Jian Chuan ^a   Zhang, Xiao Shi ^a   Zheng, Li Min ^a   Guo, Xiang ^a,b   Qian, Chao Nan ^a,b   Mai, Hai Qiang ^a,b   Zeng, Yi Xin ^a   more..

^a SUN YAT SEN UNIVERSITY CANCER CENTER   (China)

^b Department of Nasopharyngeal Carcinoma ^*  (China)

Author keywords

Adoptive cell therapy; Nasopharyngeal carcinoma; Tumor infiltrating lymphocytes

Indexed keywords

CELL THERAPY AGENT; CISPLATIN; EPSTEIN BARR VIRUS ANTIGEN; GAMMA INTERFERON;

ADOPTIVE CELL THERAPY; ADULT; ALLERGIC REACTION; ALOPECIA; ANEMIA; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER IMMUNOTHERAPY; CANCER STAGING; CELL THERAPY; CHEMORADIOTHERAPY; CLINICAL ARTICLE; CLINICAL TRIAL (TOPIC); CONTROLLED STUDY; DIARRHEA; DISEASE FREE SURVIVAL; ENZYME LINKED IMMUNOSORBENT ASSAY; ENZYME LINKED IMMUNOSPOT ASSAY; FATIGUE; FEMALE; FLOW CYTOMETRY; GENE EXPRESSION; HEMATOLOGIC DISEASE; HUMAN; IMMUNE RESPONSE; IMMUNOHISTOCHEMISTRY; INFECTION; INTENSITY MODULATED RADIATION THERAPY; LEUKOPENIA; LYMPHOCYTOPENIA; MALE; METASTATIC MELANOMA; MIDDLE AGED; MUCOSA INFLAMMATION; NASOPHARYNX CARCINOMA; NAUSEA; NEUTROPENIA; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL (TOPIC); RADIATION DERMATITIS; THROMBOCYTOPENIA; TUMOR ASSOCIATED LEUKOCYTE; TUMOR REGRESSION; VIRUS LOAD; VOMITING;

EID: 84954472663     PISSN: 21624011     EISSN: 2162402X     Source Type: Journal    
DOI: 10.4161/23723556.2014.976507     Document Type: Article

References (48)

1. Li J, Zeng XH, Mo HY, Rolen U, Gao YF, Zhang XS, Chen QY, Zhang L, Zeng MS, Li MZ et al. Functional inactivation of EBV-specific T-lympho-cytes in nasopharyngeal carcinoma: implications for tumor immunotherapy. PLoS One 2007; 2:e1122; PMID:17987110; http://dx.doi.org/10.1371/journal.pone.0001122
2. Cao SM, Simons MJ, Qian CN. The prevalence and prevention of nasopharyngeal carcinoma in China. Chinese J Cancer 2011; 30:114-9; PMID:21272443; http://dx.doi.org/10.5732/cjc.010.10377
3. Dechaphunkul T, Pruegsanusak K, Sangthawan D, Sunpaweravong P. Concurrent chemoradiotherapy with carboplatin followed by carboplatin and 5-fluoro-uracil in locally advanced nasopharyngeal carcinoma. Head Neck Oncol 2011; 3:30; PMID:21639934; http://dx.doi.org/10.1186/1758-3284-3-30
4. Chen MY, Jiang R, Guo L, Zou X, Liu Q, Sun R, Qiu F, Xia ZJ, Huang HQ, Zhang L et al. Locoregional radiotherapy in patients with distant metastases ofnaso-pharyngeal carcinoma at diagnosis. Chinese J Cancer 2013; 32:604-13; PMID:24206918; http://dx.doi.org/10.5732/cjc.013.10148
5. Huncharek M, Kupelnick B. Combined chemoradia- tion versus radiation therapy alone in locally advanced nasopharyngeal carcinoma: results of a meta-analysis of 1,528 patients from six randomized trials. Am J Clin Oncology 2002; 25:219-23; PMID:12040275; http://dx.doi.org/10.1097/00000421-200206000-00002
6. Langendijk JA, Leemans CR, Buter J, Berkhof J, Slot- man BJ. The additional value of chemotherapy to radiotherapy in locally advanced nasopharyngeal carcinoma: a meta-analysis of the published literature. J Clin Oncol 2004; 22:4604-12; PMID:15542811; http://dx.doi.org/10.1200/JCO.2004.10.074
7. Baujat B, Audry H, Bourhis J, Chan AT, Onat H, Chua DT, Kwong DL, Al-Sarraf M, Chi KH, Hare-yama M et al. Chemotherapy in locally advanced nasopharyngeal carcinoma: an individual patient data metaanalysis of eight randomized trials and 1753 patients. Int J Radiat Oncol Biol Phys 2006; 64:47-56; PMID:16377415
8. Chen L, Hu CS, Chen XZ, Hu GQ, Cheng ZB, Sun Y, Li WX, Chen YY, Xie FY, Liang SB et al. Concurrent chemoradiotherapy plus adjuvant chemotherapy versus concurrent chemoradiotherapy alone in patients with locoregionally advanced nasopharyngeal carcinoma: a phase 3 multicentre randomised controlled trial. Lancet Oncol 2012; 13:163-71; PMID:22154591; http://dx.doi.org/10.1016/S1470-2045(11)70320-5
9. Dawson CW, Rickinson AB, Young LS. Epstein-Barr virus latent membrane protein inhibits human epithelial cell differentiation. Nature 1990; 344:777-80; PMID:2158628; http://dx.doi.org/10.1038/344777a0
10. Gourzones C, Barjon C, Busson P. Host-tumor interactions in nasopharyngeal carcinomas. Semin Cancer Biol Res 2012; 2012; 22:127-36; PMID:22249142; http://dx.doi.org/10.1016/j.semcancer.2012.01.002
11. Lee SP. Nasopharyngeal carcinoma and the EBV-specific T cell response: prospects for immunotherapy. Seminars Cancer Biol 2002;12:463-71; PMID:12450732; http://dx.doi.org/10.1016/S1044-579X(02)00089-5
12. Mazeron MC. Value of anti-Epstein-Barr antibody detection in the diagnosis and management of undifferentiated carcinoma of the nasopharynx. Bull Cancer Radiother 1996; 83:3-7; PMID:8679277
13. Gottschalk S, Heslop HE, Rooney CM. Adoptive immunotherapy for EBV-associated malignancies. Leuk Lymphoma 2005; 46:1-10; PMID:15621775; http://dx.doi.org/10.1080/10428190400002202
14. Straathof KC, Bollard CM, Popat U, Huls MH, Lopez T, Morriss MC, Gresik MV, Gee AP, Russell HV, Brenner MK et al. Treatment of nasopharyngeal carcinoma with Epstein-Barr virus-specific T lymphocytes. Blood 2005; 105:1898-904; PMID:15542583; http://dx.doi.org/10.1182/blood-2004-07-2975
15. Comito MA, Sun Q, Lucas KG. Immunotherapy for Epstein-Barr virus-associated tumors. Leuk Lymphoma 2004; 45:1981-7; PMID:15370241; http://dx.doi.org/10.1080/10428190410001700831
16. Comoli P, De Palma R, Siena S, Nocera A, Basso S, Del Galdo F, Schiavo R, Carminati O, Tagliamacco A, Abbate GF et al. Adoptive transfer of allogeneic Epstein-Barr virus (EBV)-specific cytotoxic T cells with in vitro antitumor activity boosts LMP2-specific immune response in a patient with EBV-related nasopharyngeal carcinoma. Ann Oncol 2004; 15:113-7; PMID:14679129; http://dx.doi.org/10.1093/annonc/mdh027
17. Bollard CM, Aguilar L, Straathof KC, Gahn B, Huls MH, Rousseau A, Sixbey J, Gresik MV, Carrum G, Hudson M et al. Cytotoxic T lymphocyte therapy for Epstein-Barr virusC Hodgkin’s disease. J Exp Med 2004; 200:1623-33; PMID:15611290; http://dx.doi.org/10.1084/jem.20040890
18. Lucas KG, Salzman D, Garcia A, Sun Q. Adoptive immunotherapy with allogeneic Epstein-Barr virus (EBV)-specific cytotoxic T-lymphocytes for recurrent, EBV-positive Hodgkin disease. Cancer 2004; 100:1892-901; PMID:15112270; http://dx.doi.org/10.1002/cncr.20188
19. Sun Q, Burton R, Reddy V, Lucas KG. Safety ofalloge-neic Epstein-Barr virus (EBV)-specific cytotoxic T lymphocytes for patients with refractory EBV-related lymphoma. British journal of haematology 2002; 118:799-808; PMID:12181048; http://dx.doi.org/10.1046/j.1365-2141.2002.03683.x
20. Smith C, Tsang J, Beagley L, Chua D, Lee V, Li V, Moss DJ, Coman W, Chan KH, Nicholls J et al. Effective treatment of metastatic forms of Epstein-Barr virus-associated nasopharyngeal carcinoma with a novel adenovirus-based adoptive immunotherapy. Cancer Res 2012; 72:1116-25; PMID:22282657; http://dx.doi.org/10.1158/0008-5472.CAN-11-3399
21. Lutzky VP, Davis JE, Crooks P, Corban M, Smith MC, Elliott M, Morrison L, Cross S, Tscharke D, Pan- izza B et al. Optimization of LMP-specific CTL expansion for potential adoptive immunotherapy in NPC patients. Immunol Cell Biol 2009; 87:481-8; PMID: 19468283; http://dx.doi.org/10.1038/icb.2009.25
22. Louis CU, Straathof K, Bollard CM, Gerken C, Huls MH, Gresik MV, Wu MF, Weiss HL, Gee AP, Brenner MK et al. Enhancing the in vivo expansion ofadop- tively transferred EBV-specific CTL with lymphodepleting CD45 monoclonal antibodies in NPC patients. Blood 2009; 113:2442-50; PMID:18971421; http://dx.doi.org/10.1182/blood-2008-05-157222
23. Besser MJ, Shapira-Frommer R, Treves AJ, Zippel D, Itzhaki O, Hershkovitz L, Levy D, Kubi A, Hovav E, Chermoshniuk N et al. Clinical responses in a phase II study using adoptive transfer of short-term cultured tumor infiltration lymphocytes in metastatic melanoma patients. Clin Cancer Res 2010; 16:2646-55; PMID:20406835; http://dx.doi.org/10.1158/1078-0432.CCR-10-0041
24. Benlalam H, Vignard V, Khammari A, Bonnin A, Godet Y, Pandolfino MC, Jotereau F, Dreno B, Labar-riere N. Infusion of Melan-A/Mart-1 specific tumor-infiltrating lymphocytes enhanced relapse-free survival of melanoma patients. Cancer Immunol Immunother 2007; 56:515-26; PMID:16874485; http://dx.doi.org/10.1007/s00262-006-0204-0
25. Kradin RL, Kurnick JT, Lazarus DS, Preffer FI, Dubi- nett SM, Pinto CE, Gifford J, Davidson E, Grove B, Callahan RJ et al. Tumour-infiltrating lymphocytes and interleukin-2 in treatment of advanced cancer. Lancet 1989; 1:577-80; PMID:2564111; http://dx.doi.org/10.1016/S0140-6736(89)91609-7
26. Rosenberg SA, Yang JC, Sherry RM, Kammula US, Hughes MS, Phan GQ, Citrin DE, Restifo NP, Robbins PF, Wunderlich JR et al. Durable complete responses in heavily pretreated patients with metastatic melanoma using T-cell transfer immunotherapy. Clin Cancer Res 2011; 17:4550-7; PMID:21498393; http://dx.doi.org/10.1158/1078-0432.CCR-11-0116
27. Muranski P, Boni A, Wrzesinski C, Citrin DE, Rosen berg SA, Childs R, Restifo NP. Increased intensity lym-phodepletion and adoptive immunotherapy-how far can we go? Nat Clin Pract Oncol 2006; 3:668-81; PMID:17139318; http://dx.doi.org/10.1038/ncponc0666
28. He J, Tang XF, Chen QY, Mai HQ, Huang ZF, Li J, Zeng YX. Ex vivo expansion of tumor-infiltrating lymphocytes from nasopharyngeal carcinoma patients for adoptive immunotherapy. Chinese J Cancer 2012; 31:287-94; PMID:22257383.
29. Kalpoe JS, Dekker PB, van Krieken JH, Baatenburg de Jong RJ, Kroes AC. Role of Epstein–Barr virus DNA measurement in plasma in the clinical management of nasopharyngeal carcinoma in a low risk area. J Clin Pathol 2006; 59:537-41; PMID:16489178; http://dx.doi.org/10.1136/jcp.2005.030544
30. Chan AT, Lo YM, Zee B, Chan LY, Ma BB, Leung SF, Mo F, Lai M, Ho S, Huang DP et al. Plasma Epstein- Barr virus DNA and residual disease after radiotherapy for undifferentiated nasopharyngeal carcinoma. J Natl Cancer Inst 2002; 94:1614-9; PMID:12419787; http://dx.doi.org/10.1093/jnci/94.21.1614
31. Weber J, Atkins M, Hwu P, Radvanyi L, Sznol M, Yee C, Immunotherapy Task Force of the NCIIDSC. White paper on adoptive cell therapy for cancer with tumor-infiltrating lymphocytes: a report of the CTEP subcommittee on adoptive cell therapy. Clin Cancer Res 2011; 17:1664-73;PMID:21325070; http://dx.doi.org/10.1158/1078-0432.CCR-10-2272
32. Yee C. Adoptive T-cell therapy for cancer: boutique therapy or treatment modality? Clin Cancer Res 2013; 19:4550-2; PMID:23922301; http://dx.doi.org/10.1158/1078-0432.CCR-13-1367
33. Wu R, Forget MA, Chacon J, Bernatchez C, Haymaker C, Chen JQ, Hwu P, Radvanyi LG. Adoptive T-cell therapy using autologous tumor-infiltrating lymphocytes for metastatic melanoma: current status and future outlook. Cancer J 2012; 18:160-75; PMID:22453018; http://dx.doi.org/10.1097/PPO.0b013e31824d4465
34. Louis CU, Straathof K, Bollard CM, Ennamuri S, Gerken C, Lopez TT, Huls MH, Sheehan A, Wu MF, Liu H et al. Adoptive transfer of EBV-specific T cells results in sustained clinical responses in patients with locoregional nasopharyngeal carcinoma. J Immunother 2010; 33:983-90; PMID:20948438; http://dx.doi.org/10.1097/CJI.0b013e3181f3cbf4
35. Comoli P, Pedrazzoli P, Maccario R, Basso S, Carmi-nati O, Labirio M, Schiavo R, Secondino S, Frasson C, Perotti C et al. Cell therapy of stage IV nasopharyngeal carcinoma with autologous Epstein-Barr virus-targeted cytotoxic T lymphocytes. J Clinl Oncol 2005; 23:8942-9; PMID:16204009; http://dx.doi.org/10.1200/JCO.2005.02.6195
36. Lin CL, Lo WF, Lee TH, Ren Y, Hwang SL, Cheng YF, Chen CL, Chang YS, Lee SP, Rickinson AB et al. Immunization with Epstein-Barr Virus (EBV) peptide-pulsed dendritic cells induces functional CD8+T-cell immunity and may lead to tumor regression in patients with EBV-positive nasopharyngeal carcinoma. Cancer Res 2002; 62:6952-8; PMID:12460912
37. Shi H, Liu L, Wang Z. Improving the efficacy and safety of engineered T cell therapy for cancer. Cancer letters 2013; 328:191-7; PMID:23022475; http://dx.doi.org/10.1016/j.canlet.2012.09.015
38. Radvanyi LG, Bernatchez C, Zhang M, Fox PS, Miller P, Chacon J, Wu R, Lizee G, Mahoney S, Alvarado G et al. Specific lymphocyte subsets predict response to adoptive cell therapy using expanded autologous tumor-infiltrating lymphocytes in metastatic melanoma patients. Clin Cancer Res 2012; 18:6758-70;PMID:23032743; http://dx.doi.org/10.1158/1078-0432.CCR-12-1177
39. Dudley ME. Adoptive cell therapy for patients with melanoma. J Cancer 2011; 2:360-2; PMID:21716716; http://dx.doi.org/10.7150/jca.2.360
40. Dudley ME, Yang JC, Sherry R, Hughes MS, Royal R, Kammula U, Robbins PF, Huang J, Citrin DE, Leit-man SF et al. Adoptive cell therapy for patients with metastatic melanoma: evaluation of intensive myeloa-blative chemoradiation preparative regimens. J Clin Oncol 2008; 26:5233-9; PMID:18809613; http://dx.doi.org/10.1200/JCO.2008.16.5449
41. Chapuis AG, Thompson JA, Margolin KA, Rodmyre R, Lai IP, Dowdy K, Farrar EA, Bhatia S, Sabath DE, Cao J et al. Transferred melanoma-specific CD8+T cells persist, mediate tumor regression, and acquire central memory phenotype. Proc Natl Acad Sci U S A 2012; 109:4592-7; PMID:22393002; http://dx.doi.org/10.1073/pnas.1113748109
42. Rosenberg SA, Dudley ME. Adoptive cell therapy for the treatment of patients with metastatic melanoma. Curr Opin Immunol 2009; 21:233-40; PMID:19304471; http://dx.doi.org/10.1016/j.coi.2009.03.002
43. Secondino S, Zecca M, Licitra L, Gurrado A, Schia- vetto I, Bossi P, Locati L, Schiavo R, Basso S, Baldanti F et al. T-cell therapy for EBV-associated nasopharyngeal carcinoma: preparative lymphodepleting chemotherapy does not improve clinical results. Ann Oncol 2012; 23:435-41; PMID:21586688; http://dx.doi.org/10.1093/annonc/mdr134
44. Dudley ME, Gross CA, Langhan MM, Garcia MR, Sherry RM, Yang JC, Phan GQ, Kammula US, Hughes MS, Citrin DE et al. CD8+enriched “young” tumor infiltrating lymphocytes can mediate regression of metastatic melanoma. Clin Cancer Res 2010; 16:6122-31; PMID:20668005; http://dx.doi.org/10.1158/1078-0432.CCR-10-1297
45. Zhou J, Shen X, Huang J, Hodes RJ, Rosenberg SA, Robbins PF. Telomere length of transferred lymphocytes correlates with in vivo persistence and tumor regression in melanoma patients receiving cell transfer therapy. J Immunol 2005; 175:7046-52; PMID: 16272366; http://dx.doi.org/10.4049/jimmunol.175.10.7046
46. Paludan C, Schmid D, Landthaler M, Vockerodt M, Kube D, Tuschl T, Munz C. Endogenous MHC class II processing ofa viral nuclear antigen after autophagy. Sci 2005; 307:593-6; PMID:15591165; http://dx.doi.org/10.1126/science.1104904
47. Cejas PJ, Walsh MC, Pearce EL, Han D, Harms GM, Artis D, Turka LA, Choi Y. TRAF6 inhibits Th17 differentiation and TGF-beta-mediated suppression of IL-2. Blood 2010; 115:4750-7; PMID:20351308; http://dx.doi.org/10.1182/blood-2009-09-242768
48. Jin J, Sabatino M, Somerville R, Wilson JR, Dudley ME, Stroncek DF, Rosenberg SA. Simplified method ofthe growth ofhuman tumor infiltrating lymphocytes in gas-permeable flasks to numbers needed for patient treatment. J Immunother 2012; 35:283-92; PMID: 22421946; http://dx.doi.org/10.1097/CJI.0b013e31824e801f